Lawyers in our firm’s Mass Torts Section continue to pursue claims on behalf of individuals who have been injured and damaged as a result of taking Risperdal. As we have previously reported, Risperdal is the brand name drug manufactured by Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson. The drug went on the market in 1993 after receiving approval from the FDA for the treatment of schizophrenia. In 2003, the drug was approved for short-term treatment of acute manic/mixed episodes associated with Bipolar I Disorder in adults.
Until 2006, the drug was not approved for any indication to treat minors. In 1997, the FDA denied a request by Janssen for a pediatric indication for the drug. Despite this denial, Janssen marketed the drug for the treatment of depression, anxiety, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), conduct disorder, sleep disorders, anger management and mood enhancement/stabilization.
In 2006, Janssen obtained approval to market the drug for autistic irritability for children and adolescents between the ages of 5 to 16 years old. In 2007, Janssen obtained approval to market the drug for treatment of schizophrenia in adolescents between the ages of 13 to 17 years old and short-term treatment of manic or mixed episodes of Bipolar I Disorder in children and adolescents between the ages of 10 to 17 years old.
Use of Risperdal can cause gynecomastia (enlarged breasts in males), galactorrhea (milky nipple discharge), weight gain, hyperglycemia, diabetes and inhibited reproductive function. In a January 2015 Risperdal trial in Philadelphia, a former FDA commissioner testified that Janssen was aware of a link between breast enlargement in adolescent males long before it updated the label to adequately warn about the risk. The former commissioner also testified that Janssen attempted to downplay the risks of gynecomastia in the scientific literature. The jury returned a $2.5 million verdict against Janssen at the end of that trial.
In March 2015, a second Risperdal trial in Philadelphia resulted in a verdict in favor of Janssen. In the March case, the Plaintiff stopped taking Risperdal in 2006 and gynecomastia was not diagnosed until 2014. The jury concluded that Janssen was negligent in failing to warn about the risks of Risperdal, but that the drug did not cause the Plaintiff’s injuries.
If you need more information on this subject or have a potential claims as a result of taking Risperdal, contact James Lampkin, a lawyer in our firm’s Mass Torts Section, at 800-898-2034 or by email at James.Lampkin@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.